RXRX
Recursion Pharmaceuticals, Inc.
NASDAQ · USHealthcareBiotechnology
$2.88-2.38%
Price as of Jul 20, 2026
RXRX ownership
Recursion Pharmaceuticals, Inc. ownership & insider activity
Latest available institutional positioning and SEC Form 4 insider transactions, coalesced at the company entity level when listings share coverage.
Insider Activity
Sentiment
0/100
Buys (3m)
0
Sells (3m)
10
Net (3m)
-$1.0M
Insider trades by month Buys Sells
Feb
Mar
Apr
May
Jun
Jul
Context3-month price -20.1%Institutions accumulating (13F)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 9, 2026 | Borgeson Blakedirector | Sell | 40,000 | $3.96 |
| Jul 2, 2026 | Li Dean Ydirector | Grant | 3,747 | — |
| Jul 2, 2026 | Dar Zavaindirector | Grant | 5,109 | — |
| Jun 22, 2026 | Bumpus Namandjedirector | Sell | 3,963 | $3.18 |
| Jun 22, 2026 | Michor Franziskadirector | Grant | 88,424 | — |
| Jun 22, 2026 | Borgeson Blakedirector | Grant | 88,424 | — |
| Jun 22, 2026 | HERSHBERG ROBERTdirector | Grant | 88,424 | — |
| Jun 22, 2026 | Bumpus Namandjedirector | Grant | 88,424 | — |
| Jun 22, 2026 | Li Dean Ydirector | Grant | 88,424 | — |
| Jun 22, 2026 | Sun Elaine Ddirector | Grant | 88,424 | — |
| Jun 22, 2026 | Dar Zavaindirector | Grant | 88,424 | — |
| Jun 17, 2026 | Taylor Ben Rofficer: Chief Financial Officer | Tax | 5,396 | $3.15 |
| Jun 5, 2026 | Khan Najatdirector, officer: CEO and President | Sell | 23,588 | $3.58 |
| Jun 5, 2026 | Gibson Christopherdirector | Sell | 40,000 | $3.62 |
| Jun 4, 2026 | Bumpus Namandjedirector | Sell | 4,386 | $3.54 |
| Jun 4, 2026 | Borgeson Blakedirector | Sell | 30,000 | $3.68 |
| May 27, 2026 | Gibson Christopherdirector | Sell | 40,000 | $3.08 |
| May 19, 2026 | Hallett Davidofficer: Chief Scientific Officer | Tax | 26,657 | $3.04 |
| May 19, 2026 | Gibson Christopherdirector | Tax | 22,821 | $3.04 |
| May 19, 2026 | Taylor Ben Rofficer: Chief Financial Officer | Tax | 25,018 | $3.04 |
| May 19, 2026 | Khan Najatdirector, officer: CEO and President | Tax | 62,701 | $3.04 |
| May 8, 2026 | Gibson Christopherdirector | Sell | 40,000 | $3.37 |
| May 7, 2026 | Borgeson Blakedirector | Sell | 30,000 | $3.52 |
| Apr 24, 2026 | Gibson Christopherdirector | Sell | 40,000 | $3.61 |
| Apr 8, 2026 | Taylor Ben Rofficer: Chief Financial Officer | Tax | 48,028 | $3.11 |
| Apr 8, 2026 | Gibson Christopherdirector | Sell | 40,000 | $3.10 |
| Apr 8, 2026 | Borgeson Blakedirector | Sell | 30,000 | $3.10 |
| Apr 2, 2026 | Dar Zavaindirector | Grant | 4,902 | — |
| Apr 2, 2026 | Li Dean Ydirector | Grant | 3,268 | — |
| Mar 25, 2026 | Gibson Christopherdirector | Sell | 40,000 | $3.25 |
Source: RXRX SEC Form 4 filings, latest Jul 9, 2026. For informational purposes only — not investment advice.
Institutional activity (13F)
How institutions changed their RXRX positions over the last 6 months (SEC Form 13F).
Increased
272
New positions
120
Reduced
174
Sold out
95
Largest moves
| Institution | Action | Shares | Filed |
|---|---|---|---|
| VANGUARD GROUP INC | Increased | 47.2M | Jan 29, 2026 |
| BLACKROCK, INC. | Increased | 43.2M | May 13, 2026 |
| ARK INVESTMENT MANAGEMENT LLC | Increased | 40.2M | May 12, 2026 |
| BLACKROCK, INC. | Increased | 38.9M | Feb 12, 2026 |
| ARK INVESTMENT MANAGEMENT LLC | Increased | 37.3M | Feb 11, 2026 |
| STATE STREET CORP | Increased | 28.5M | May 15, 2026 |
| STATE STREET CORP | Increased | 25.3M | Feb 13, 2026 |
| BAILLIE GIFFORD & CO | Reduced | 23.8M | Jan 23, 2026 |
| BAILLIE GIFFORD & CO | Reduced | 23.7M | May 8, 2026 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | New Position | 22.8M | May 8, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 22.2M | May 15, 2026 |
| SOFTBANK GROUP CORP. | Reduced | 13.6M | Feb 17, 2026 |
| SOFTBANK GROUP CORP. | Unchanged | 13.6M | May 15, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | Increased | 12.3M | May 15, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | Increased | 10.9M | Feb 9, 2026 |
Source: SEC Form 13F filings. For informational purposes only — not investment advice.